In a chat with ET Now, Sarabjit Kour Nangra, Angel Broking, says since Ipca was already under import alert, the warning letter now means th...

"ANDA approval will add to the company but since the company is so big that such small approvals do not add significantly."

"They have not given any idea on their guidance for the full year so far, but I guess the way they have been doing, they should be able to ...

"Most of the IT companies have been pointing towards a healthy (revenue filled) full year, which should entail a healthy first quarter."

I believe the overall stock reaction today is in view of the same. Secondly, Sun Pharma management has refrained from giving any guidance f...

The stock ended 3.35 per cent lower at Rs 1,690.60 on the BSE. During the day, it slipped 3.95 per cent to Rs 1,680.

They have been guiding again and again that FY17 onwards, they expect Infosys to be back being the bellwether company in terms of the IT se...

"Sales are in line, as you said, and definitely even PAT is higher than our expectations."

Shares of IPCA Laboratories ended with sharp losses of 10.5 per cent, wiping-out Rs 995 crore from its market valuation today, amid reports...

Shares of IPCA Laboratories slumped nearly 16 per cent to hit its 52-week low in early trade amid reports of stock downgrade.

The stock has fallen on reports that Halol plant in Gujarat has been subjected to surprise inspection by the American drug regulator USFDA.

The facility is important for the company as its contributes to around 40 per cent of US sales and around 25 per cent of consolidated profi...

Sanofi India's stock tanked 10.22 per cent to settle at Rs 2,900. In intra-day trade, the scrip plunged 10.99 per cent to Rs 2,875.

Lupin reported a net profit of Rs 553 cr for the quarter ended March 204, up 35.5%, from Rs 408 cr in the corresponding quarter last fiscal.

Shares of Ranbaxy Laboratories today settled for the day with losses of 1.51 %, pursuant to which the market capitalisation eroded by Rs 43...

In an interview with ET Now, Sarabjit Kour Nangra, VP–Research-Pharma, Angel Broking, shares her views on some pharma stocks. Excerpts:

In an interview with ET Now, Sarabjit Kour Nangra, VP–Research: Pharma, Angel Broking, gives her views on Lupin’s expected earnings. Excerp...